Table 5 Characteristics of patients following initial TACE with AFP ≥ 200 ng/ml vs. < 200 ng/ml
Repeat serum AFP subgroup n = 177 | Â | Â | Â | Â | Â |
|---|---|---|---|---|---|
Variable | n | AFP < 200 ng/ml | n | AFP ≥ 200 ng/ml | P value |
Pre-TACE, % (n) | |||||
 Caucasian | 147 | 83.7% (123) | 30 | 63.3% (19) | 0.011 |
 HCV | 147 | 41.5% (61) | 30 | 70% (21) | 0.004 |
 HBV | 147 | 17.7% (26) | 30 | 33.3% (10) | 0.05 |
 T2DM | 147 | 34.7% (51) | 30 | 16.7% (5) | 0.05 |
 BCLC stage C | 147 | 2% (3) | 30 | 13.3% (4) | 0.017 |
 Macrovascular invasion | 147 | 1.4% (2) | 30 | 10% (3) | 0.035 |
 tumour size, (cm), mean (SD) | 147 | 3.84 (2.55) | 30 | 5.64 (3.89) | 0.002 |
Post initial TACE, median (IQR) | |||||
 Neutrophils, x10^9/L | 91 | 2.9 [2.3-3.72] | 23 | 4.2 [2.9-5.1] | 0.001 |
 ALT, U/L | 146 | 38.5 [24-72] | 29 | 65 [34-100] | 0.03 |
 Na, mmol/L | 145 | 138 [136-140] | 28 | 137 [135-139] | 0.048 |